Karista
Karista is a venture capital firm established in 2001 and located in Paris, France. The firm specializes in incubation and early-stage investments, focusing on a diverse range of sectors including healthcare, information and communication technology, nanotechnology, and clean technology. It actively invests in startups engaged in biotechnology, medical equipment, digital technologies, deep tech, and newspace, among other areas. Karista typically directs investments ranging from €0.5 million to €5 million in companies with revenues up to €4 million. The firm primarily operates within France, particularly in the Ile-de-France region and Paris, and has supported over 90 companies over the past two decades, emphasizing partnerships with entrepreneurs who share a common vision.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Paris
UpFactor
Seed Round in 2019
Founded in 2017, UpFactor specializes in site analysis services using GIS technology. It aggregates data such as addresses, street widths, building heights, land use plans, solar potential registers, and protected areas to assess building potentials.
Admo.tv
Series B in 2019
Admo.tv is the best TV analytics platform that helps TV & radio advertisers to measure and optimise the online impact of their offline investments. Admo.tv optimises, in average, about 30% the R.O.I. of its clients by providing the finest analysis in terms of incremental visits and conversion of their media investments. Admo.tv is a start-up that has offices in Paris and operates in more than 12 different countries worldwide. Admo.tv optimise every day the offline investments of the best advertising agencies (Dentsu Aegis, Havas…) and top-tier brands such as Accor, Allianz, Ford, Meetic, La Redoute, and more.
Acticor Biotech
Series B in 2018
Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.
Acticor Biotech
Series B in 2018
Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.
Appscho
Seed Round in 2018
AppScho, SAS, established in 2014 and headquartered in Paris, France, specializes in mobile application software for higher education. Its application centralizes essential information for students and educational institutions, providing access to schedules, grades, school events, and employment opportunities. The app enhances student engagement by offering features such as course previews, classroom details, and notifications for schedule changes. Additionally, it facilitates communication between institutions and students, allowing educators to monitor student engagement and analyze performance. By streamlining campus content and services, AppScho aims to improve the overall academic experience and support students in managing their studies effectively.
Acticor Biotech
Series A in 2018
Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.
Acticor Biotech
Venture Round in 2017
Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.
BnbSitter
Series A in 2016
BnbSitter, established in 2013 and headquartered in Paris, France, specializes in streamlining short-term rental management. Through its online platform, the company offers on-demand concierge services, enabling vacation rental hosts to book essential services like guest check-in/check-out and rental cleaning swiftly and efficiently, ensuring a smooth and welcoming experience for guests.
e(ye)BRAIN
Series B in 2012
e(ye)BRAIN SA is a medical company specializing in the development and manufacturing of eye trackers designed for the diagnosis of neurological and psychiatric diseases. Founded in 2008 and based in Paris, France, the company offers two primary products: EyeBrain T1 and EyeBrain T2. The EyeBrain T1 allows users to record eye movements, while the EyeBrain T2 incorporates advanced algorithms to capture both eye and head movements. These recorded movements are then analyzed using the MeyeEval software. In addition to its product offerings, e(ye)BRAIN provides advisory, paradigm development, training, and support services to its clients, enhancing their capabilities in clinical research and functional exploration of both healthy and diseased brains.
e(ye)BRAIN
Series A in 2009
e(ye)BRAIN SA is a medical company specializing in the development and manufacturing of eye trackers designed for the diagnosis of neurological and psychiatric diseases. Founded in 2008 and based in Paris, France, the company offers two primary products: EyeBrain T1 and EyeBrain T2. The EyeBrain T1 allows users to record eye movements, while the EyeBrain T2 incorporates advanced algorithms to capture both eye and head movements. These recorded movements are then analyzed using the MeyeEval software. In addition to its product offerings, e(ye)BRAIN provides advisory, paradigm development, training, and support services to its clients, enhancing their capabilities in clinical research and functional exploration of both healthy and diseased brains.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.